Close Menu

At a conference yesterday, Merck's Merv Turner said big pharma's problems are due to researchers, reports Science Insider. "Seventy-five cents of every dollar we spend on R&D goes to fund failure," Turner said. He added that Merck is undergoing "painful" restructuring after acquiring Schering-Plough and that one area that will likely be pared down is late-stage drug development -- though "nothing's safe from cuts."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.